PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 7509322-0 1994 Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Dextrans 57-64 epidermal growth factor Homo sapiens 33-56 10938398-0 2000 Binding of 125I after administration of 125I-EGF-dextran, 125I-EGF or 125I to human bladder cancer spheroids. Dextrans 49-56 epidermal growth factor Homo sapiens 45-48 10938398-1 2000 The binding of a targeting agent, 125I-EGF-dextran, to epidermal growth factor (EGF) receptors in tumour spheroids of a human bladder cancer cell line was studied. Dextrans 43-50 epidermal growth factor Homo sapiens 39-42 10938398-1 2000 The binding of a targeting agent, 125I-EGF-dextran, to epidermal growth factor (EGF) receptors in tumour spheroids of a human bladder cancer cell line was studied. Dextrans 43-50 epidermal growth factor Homo sapiens 55-78 10938398-1 2000 The binding of a targeting agent, 125I-EGF-dextran, to epidermal growth factor (EGF) receptors in tumour spheroids of a human bladder cancer cell line was studied. Dextrans 43-50 epidermal growth factor Homo sapiens 80-83 10938398-2 2000 The accumulation of radioactivity was continuous up to at least 48 h in the peripheral cells of the spheroids, which in comparison with the binding pattern of 125I-EGF indicated that the cells had a limited capacity to degrade the EGF-dextran. Dextrans 235-242 epidermal growth factor Homo sapiens 231-234 10938398-3 2000 The 125I-EGF-dextran was of two different sizes, 28 and 76 kDa, but this did not affect the binding patterns and the results were very similar. Dextrans 13-20 epidermal growth factor Homo sapiens 9-12 9627668-0 1998 Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression. Dextrans 46-53 epidermal growth factor Homo sapiens 22-45 12373311-0 2002 EGF and dextran-conjugated EGF induces differential phosphorylation of the EGF receptor. Dextrans 8-15 epidermal growth factor Homo sapiens 27-30 12373311-1 2002 Dextran-conjugated EGF (EGF-dextran) has a potential use for targeted radionuclide therapy of tumors that overexpress the epidermal growth factor receptor (EGFR). Dextrans 0-7 epidermal growth factor Homo sapiens 19-22 12373311-1 2002 Dextran-conjugated EGF (EGF-dextran) has a potential use for targeted radionuclide therapy of tumors that overexpress the epidermal growth factor receptor (EGFR). Dextrans 0-7 epidermal growth factor Homo sapiens 24-35 11096240-0 2000 Intravesical administration of EGF- dextran conjugates in patients with superficial bladder cancer. Dextrans 36-43 epidermal growth factor Homo sapiens 31-34 11096240-3 2000 The aim of this study was to determine if intravesically administered EGF-dextran conjungate selectively accumulated in the tumor tissue and to correlate the uptake to tumor characteristics. Dextrans 74-81 epidermal growth factor Homo sapiens 70-73 11096240-6 2000 RESULTS: Five patients received EGF-dextran-(99m)Tc, three received dextran-(99m)Tc and one received only (99m)Tc. Dextrans 36-43 epidermal growth factor Homo sapiens 32-35 11096240-9 2000 CONCLUSION: The results are encouraging and further studies are warranted to investigate if EGF-dextran could be effective as intravesical therapy, either conjugated with cystostatic drugs or labeled with suitable radionuclides. Dextrans 96-103 epidermal growth factor Homo sapiens 92-95 11004908-3 2000 Therefore EGF was conjugated to SnCe6(ED) through a carrier, such as dextran (Dex) and human serum albumin (HSA), followed by the evaluation of the photocytotoxicity on the EGF receptor overexpressing MDA-MB-468 cell line. Dextrans 69-76 epidermal growth factor Homo sapiens 10-13 11004908-3 2000 Therefore EGF was conjugated to SnCe6(ED) through a carrier, such as dextran (Dex) and human serum albumin (HSA), followed by the evaluation of the photocytotoxicity on the EGF receptor overexpressing MDA-MB-468 cell line. Dextrans 78-81 epidermal growth factor Homo sapiens 10-13 8889021-0 1996 Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Dextrans 60-67 epidermal growth factor Homo sapiens 36-59 8889021-2 1996 EGF and sulfhydryl boron hydride (BSH) were covalently coupled to an allylated 70 kDa dextran chain to form a conjugate. Dextrans 86-93 epidermal growth factor Homo sapiens 0-3 1704355-2 1991 We investigated whether EGF could be conjugated to dextran, which is a suitable carrier for toxic agents, without losing its ability to bind to the receptor. Dextrans 51-58 epidermal growth factor Homo sapiens 24-27 1813069-3 1991 In this study, the concentrations of estradiol, insulin, and EGF for optimal stimulation of T47D cell growth in 3% dextran-charcoal treated fetal bovine serum (DCC-FBS) were determined to be 1 nM, 100 nM, and 1 nM, respectively. Dextrans 115-122 epidermal growth factor Homo sapiens 61-64 1704355-4 1991 EGF was coupled to the activated dextran through the amino terminus and glycine was added to block residual activity. Dextrans 33-40 epidermal growth factor Homo sapiens 0-3 1704355-5 1991 The EGF-dextran conjugate was, after purification on Sephadex G25 and Sephacryl 200 columns, tested for its receptor binding properties on human malignant glioma, U343MGaC12:6, cells. Dextrans 8-15 epidermal growth factor Homo sapiens 4-7 1704355-11 1991 Thus, it seems promising to use dextran, conjugated with EGF, as a carrier of, for example, toxic radioactive nuclides. Dextrans 32-39 epidermal growth factor Homo sapiens 57-60